Deflazacort
Deflazacort
Definition
A synthetic glucocorticoid prodrug, with anti-inflammatory and immunomodulating properties. Upon administration, the active metabolite of deflazacort, 21-desacetyl deflazacort, binds to and activates tissue glucocorticoid receptors. This results in the inhibition of specific leukocyte functions and the inhibition of proinflammatory cytokine production.
Also known as 11Beta,21-Dihydroxy-2'-Methyl-5'Beta-H-Pregna-1,4-Dieno(17,16-D)Oxazole-3,20-Dione 21-Acetate, 5'H-Pregna-1,4-Dieno(17,16-d)Oxazole-3,20-Dione, 21-(Acetyloxy)-11-Hydroxy-2'-Methyl-, (11Beta,16Beta)-, DEFLAZACORT, Emflaza, MDL 458 — per NCIT
Also identified as
- ATC H02AB13 per RXNORM
- NCIT NCIT:C87230 per NCIT
- SCTID 116578002 per RXNORM
- SCTID 396012006 per RXNORM
- UNII KR5YZ6AE4B per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Duchenne muscular dystrophy | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Musculature | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Peripheral nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.